-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive MyelofibrosisClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Clinical Trials, Adults, Clinical Research, Clinically Relevant, Therapies, Adverse Events, Study Population
Sunday, December 12, 2021, 6:00 PM-8:00 PM

Abdulraheem Yacoub, MD1, Thamer Sliwa, MD2*, Rosa Ayala, MD, PhD3*, Roberto Ferro, MD4, Abdul Hai Mansoor, MD5*, Sue Erickson-Viitanen, PhD6*, Feng Zhou, PhD6* and Albert Assad, MD6*

1University of Kansas Cancer Center, Westwood Campus, Westwood, KS
2Hanusch Hospital, Vienna, Austria
3Hospital Universitario 12 de Octubre, CIBERONC, UCM, Madrid, Spain
4Transplant & Cellular Therapy, Avera Medical Group Hematology, Sioux Falls, SD
5Kaiser Permanente, Portland, OR
6Incyte Corporation, Wilmington, DE

Background: Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that significantly improves outcomes in patients with myelofibrosis (MF). However, a subset of patients may experience a suboptimal response to ruxolitinib alone; deeper and more durable responses in these patients may potentially be achieved by combining ruxolitinib with agents that target other signaling pathways that mediate MF pathogenesis. Consistent with this, recent phase 2 data showed that the addition of the phosphatidylinositol 3 kinase (PI3K) δ inhibitor parsaclisib to ruxolitinib monotherapy resulted in additional alleviation of MF symptoms and splenomegaly in patients with MF (Yacoub A. EHA2021. PB1716).

Aims: This phase 3, randomized, double-blind study (INCB 50465-313, NCT04551066) evaluates the combination of ruxolitinib and parsaclisib in patients with MF who are naive to JAK and PI3K inhibitor therapies.

Methods: Eligible patients are ≥18 years of age with a diagnosis of primary MF, post–polycythemia vera MF, or post-essential thrombocythemia MF, have a Dynamic International Prognostic Scoring System (DIPSS; Passamonti F. Blood. 2010;115:1703–8) risk of at least intermediate (INT)-1, palpable spleen ≥5 cm below left subcostal margin, total symptom score ≥10 at screening on the Screening Symptom Form, Eastern Cooperative Oncology Group performance status of 0–2, and a life expectancy ≥24 weeks. Patients will be excluded if they previously received therapy with any JAK inhibitor, any PI3K inhibitor, any experimental or standard drug therapy for MF ≤3 months of first study dose, have recent history of inadequate bone marrow reserve (eg, platelet count <50×109/L), or have inadequate liver or renal function at screening. Approximately 440 patients will be randomized (1:1) to ruxolitinib plus parsaclisib 5 mg once daily or ruxolitinib plus matching placebo, with stratification at randomization by DIPSS risk category (high vs INT-2 vs INT-1) and platelet count (≥100×109/L vs 50 to <100×109/L inclusive) (Figure 1). Treatment will begin on day 1, with starting ruxolitinib dose level determined by baseline platelet count and will continue as long as treatment is tolerated and discontinuation criteria are not met. When the last enrolled patient has completed 24 weeks of treatment, the study will be unblinded and patients randomized to ruxolitinib plus placebo who have adequate hematology parameters will be able to cross over to receive parsaclisib together with continued ruxolitinib. The primary objective is the evaluation and comparison of spleen volume at week 24 for patients who received ruxolitinib plus parsaclisib vs ruxolitinib plus placebo. Secondary objectives include evaluation and comparison of patient-reported MF symptoms, overall survival, time to onset and duration of response in spleen volume, and safety and tolerability of ruxolitinib plus parsaclisib vs ruxolitinib plus placebo. Sites are open across the United States, Europe, United Kingdom, and Asia.

Disclosures: Yacoub: CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Hylapharm: Current equity holder in publicly-traded company; Seattle Genetics: Honoraria, Speakers Bureau; Ardelyx: Current equity holder in publicly-traded company; Cara: Current equity holder in publicly-traded company; Dynavex: Current equity holder in publicly-traded company; Agios: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ACCELERON PHARMA: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Ayala: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria; Celgene: Honoraria. Erickson-Viitanen: Incyte: Current Employment, Current equity holder in publicly-traded company. Zhou: Incyte: Current Employment, Current equity holder in publicly-traded company. Assad: Incyte: Current Employment, Current equity holder in publicly-traded company.

*signifies non-member of ASH